Fax: 1-844-627-3827 Phone: 1-844-796-3757

## **PROGRAM OVERVIEW**

**The Trulance® Patient Assistance Program (PAP)** is designed to provide **Trulance®** at no cost to patients who are uninsured or functionally uninsured and are financially distressed. Patients are required to complete the PAP Application and provide such to Trulance Access Services, along with the necessary proof of income documentation. This program can be modified or terminated at anytime without notice by Synergy.

## **Program Eligibility**

Patients are eligible if they:

- Are a U.S. citizen or legal resident
- · Have no insurance or are functionally uninsured
- Are willing to work with Trulance Access Services to identify and apply for additional insurance coverage or assistance that may be available to them
- Meet the income requirements based on the then-current Federal Poverty Level guidelines

Any changes in insurance coverage and/ or financial circumstances while enrolled in the program may affect the patient's ability to continue to receive free product via the patient assistance program. Patients must re-apply for program eligibility at the end of each calendar year.

### **Program Enrollment Process**

To initiate the enrollment process, the office simply needs to:

- Visit the Savings and Support Page at www.trulancehcp.com
- Download and complete the Trulance® Service Request Form (SRF)
  - o If a completed SRF has already been submitted for Benefits Investigation Support, a new form will not be required; the patient will automatically be assessed for eligibility when appropriate
- Fax the completed form to Trulance Access Services at 1-844-265-0265

#### What to expect next:

- Upon receipt of the SRF, a Trulance Access Services Support Specialist will contact the patient to introduce them to the program and walk them through the enrollment process
  - o The patient will be asked to complete the Patient PAP application, which can be mailed to them or obtained online, and to submit this to Trulance Access Services along with the required financial income documentation
- Once an eligibility determination has been made, both the patient and the health care provider's office will be informed of the patient's ability to participate in the program



CALL

1-844-796-3757

This product information is intended for US audiences only. Printed in USA. | 1-888-869-8869 | TrulanceHCP.com

Trulance® is a registered trademark of Synergy Pharmaceuticals Inc.

to speak with a Trulance Access Services Support Specialist Monday through Friday from 8am-8pm ET





Fax: 1-844-627-3827 Phone: 1-844-796-3757

# **PART 1: Application**

Please complete all fields and send completed form along with necessary income documentation in order to prevent any delays.

1. Patient Information	2. Insurance Information				
First Name Last Nam	e	Primary Insura	ance	Phone #	
Sex Date of Birth (MM/DD/YYYY)		Policy Holder	Name	Relationship to Patient	
Address		Insurance ID #	:	Group #	
City State	ZIP	Secondary Ins	- Indiana	Phone #	
Cell Phone Home Phone Email Add	drace	Secondary ins	urance	Priorie #	
Preferred Method of Contact:   Cell Phone Home Phone Email		Policy Holder	Name	Relationship to Patient	
Preferred Time of Contact:	Alternoon Develling	Insurance ID # Group #		Group #	
Primary Language:	Other:				
The undersigned patient hereby represents and warrants that:  (i) I hereby authorize Trulance Access Services, contractors, and subcontractors to communicate with me via the email address provided for the purpose of providing me with information pertaining to my coverage for Trulance*, my eligibility status for the support programs offered by Synergy, and/or to communicate the need for additional information needed to accurately assess any coverage or assistance available to me for Trulance* through my insurance coverage or Synergy.		Pharmacy Ber	nefit Carrier	Phone #	
		ID#		Group #	
		Bin #		PCN #	
Handwritten signature of patient  Date					
3. Additional Insurance Information					
Are you a veteran?  Yes No If so, have you applied for VA benefits?  Yes No  Yes No Have you ever been de		assistance fr		rer been denied extra help (financial rom Social Security) through the Low sidy (LIS) Program?	
First Name Last Nam	e	Phone		Fax	
Practice Name					
Address					
City State	ZIP				



Fax: 1-844-627-3827 Phone: 1-844-796-3757

# **PART 1: Application** (continued)

5. Financial Information			
# of people in your household Adults	Children (under 18)	Proof of income that you are providing	
Total combined adjusted net income for all p	eonle	☐ Federal Tax Return	☐ Social Security Awards Letter
in your household, including all household dependents \$		☐ Pay Stubs (full months' worth within the past three months)	☐ Proof of job termination/ unemployment

Fax: 1-844-627-3827 Phone: 1-844-796-3757

### **PART 2: Release**

Please complete all fields and send completed form along with necessary income documentation in order to prevent any delays.

- (i) I understand and agree that in order to participate in this program, Trulance Access Services, contractors and subcontractors must obtain private personal information from me and my health care provider, including protected health information as defined in the Health Insurance Portability and Accountability Act of 1996 (HIPAA). This information may include name, date of birth, social security number, diagnosis, insurance information, information about my financial condition or other relevant information which Synergy deems necessary to assess my eligibility to participate in this program. Accordingly, I hereby authorize Trulance Access Services, contractors and sub-contractors to collect and maintain such information, to contact me if additional information should be required and to conduct benefit verifications and insurance research on my behalf, to contact my physician and insurer(s), including Medicare, and to exchange information with them in connection with my participation in this program.
- (ii) All information provided by me in connection with my application or participation in this program is and will always be complete and accurate and I agree that Trulance Access Services, contractors and subcontractors may verify it at any time.
- (iii) I agree to inform Trulance Access Services, contractors, and subcontractors immediately of any financial or insurance changes while enrolled in this program.
- (iv) I understand that any assistance provided under this program is contingent upon my ability to meet the eligibility criteria for the program as determined by Synergy. I acknowledge that this assistance is temporary and that I will be required to re-apply at the end of each calendar year to become eligible.
- (v) I also authorize Trulance Access Services to contact me directly in the future about available assistance programs.
- (vi) I understand that Synergy reserves the right to modify or terminate this program at any time as it deems fit, that Synergy is under no obligation to continue the program and that any decision by Synergy to modify or terminate this program will not give rise to any liability or obligation for Synergy.
- (vii) I understand that any medicines I may receive from this program are only for me and I agree that I will not give them to anyone else.
- (viii) I understand that I am receiving Trulance™ Product for free under this program, and if I am a Medicare Prescription Drug Plan or Medicare Advantage Prescription Drug Plan beneficiary, that I may not submit a claim for payment to Medicare or any third party payer, and no part of the payment for the product provided hereunder will be claimed as part of my true out-of-pocket expense (TrOOP).
- (ix) I understand that my application and enrollment in this program are not conditioned in any way on my purchase of any goods or services and that I may unsubscribe from this program at any time by contacting Trulance Access Services at 1-844-796-3757.
- (x) I understand and agree that this authorization will last for up to one (1) year from the date I sign this authorization, or until December 31st of the current year.

Patient Signature	Date

Fax: 1-844-627-3827 Phone: 1-844-796-3757

#### **Indication**

• Trulance (plecanatide) 3 mg tablets is indicated in adults for the treatment of Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation (IBS-C).

#### IMPORTANT SAFETY INFORMATION

#### WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS

Trulance® is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile mice administration of a single oral dose of plecanatide caused deaths due to dehydration. Use of Trulance should be avoided in patients 6 years to less than 18 years of age. The safety and efficacy of Trulance have not been established in pediatric patients less than 18 years of age.

#### **Contraindications**

- Trulance is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
- Trulance is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

### **Warnings and Precautions**

### **Risk of Serious Dehydration in Pediatric Patients**

- Trulance is contraindicated in patients less than 6 years of age. The safety and effectiveness of Trulance in patients less than 18 years of age have not been established. In young juvenile mice (human age equivalent of approximately 1 month to less than 2 years), plecanatide increased fluid secretion as a consequence of stimulation of guanylate cyclase-C (GC-C), resulting in mortality in some mice within the first 24 hours, apparently due to dehydration. Due to increased intestinal expression of GC-C, patients less than 6 years of age may be more likely than older patients to develop severe diarrhea and its potentially serious consequences.
- Use of Trulance should be avoided in patients 6 years to less than 18 years of age. Although there were no deaths in older juvenile mice, given the deaths in young mice and the lack of clinical safety and efficacy data in pediatric patients, use of Trulance should be avoided in patients 6 years to less than 18 years of age.

#### **Diarrhea**

- Diarrhea was the most common adverse reaction in the four placebo-controlled clinical trials for CIC and IBS-C. Severe diarrhea was reported in 0.6% of Trulance-treated CIC patients, and in 1% of Trulance-treated IBS-C patients.
- If severe diarrhea occurs, the health care provider should suspend dosing and rehydrate the patient.

#### **Adverse Reactions**

- In the two combined CIC clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (5% vs 1% placebo).
- In the two combined IBS-C clinical trials, the most common adverse reaction in Trulance-treated patients (incidence ≥2% and greater than in the placebo group) was diarrhea (4.3% vs 1% placebo).

Please also see the <u>full Prescribing Information</u>, including Box Warning, for additional risk information at www.Trulance.com.

References: 1. Trulance [package insert]. New York, NY: Synergy Pharmaceuticals Inc.

